AgenTus Therapeutics is a dynamic new start-up subsidiary developing T cell receptors (TCRs) and chimeric antigen receptors (CARs) designed to supercharge human immune effector cells to seek and destroy cancer. We aim to deliver cures to cancer patients around the world by leveraging our proprietary platforms for TCR discovery, targeting novel phosphopeptide neo-epitopes and developing unique allogeneic cell therapies. Together with our parent company, Agenus, we have a deep and diverse repertoire of immunotherapy treatments that can be used in combinations that will synergize to help the body’s immune system fight cancer.
We are a clinical stage biopharmaceutical company developing allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other life-threatening illnesses. Our iNKT cells, which we refer to as INTELLIGENT iNKT™ cells, are designed to have the innate capacity to home to the site of diseased tissue, including cancer, and recruit key components of the immune system to fight disease. iNKT cells combine properties of both T and natural killer (NK) cells and tune their response based on individual elements of the tumor or disease microenvironment. Our development pipeline includes off-the-shelf iNKT cell product candidates to treat hematologic and solid tumors. We believe these product candidates have the potential to help us treat a significantly larger patient population than is currently served by autologous Chimeric Antigen Receptor T, also known as CAR-T cell therapy.
This position is for a scientist to set up and run in vitro assay development for our allogenic cell therapy product, agenT-797, and follow-on products including CAR-iNKT. The ideal candidate will be an experienced and innovative in vitro scientist with a strong background in immunology and cancer immunotherapy. In this position you will be responsible for designing and developing novel in vitro assays for further characterization our unmodified and weaponized iNKT cell therapy products. This lab-based role’s responsibilities include the development, design and execution of in vitro preclinical studies to characterize the current cell therapy products and propose therapeutic combinations with our allogenic iNKT cell platform. This individual will generate data packages, SOPs and other related documents to contribute to IND filings. If you are an individual who is excited to take on new challenges in a dynamic start-up environment and be part of the rapidly growing team you find a warm welcome at AgenTus.